{"title":"2010-2020年阿瓦士教育医院门诊1,25-二羟基胆骨化醇与25-羟基胆骨化醇治疗两组甲状旁腺功能低下患者治疗反应相对频率及并发症发生率的比较","authors":"S. Ghaderian, A. Sadrian, H. Rashidi, A. Sedaghat","doi":"10.5114/fmpcr.2022.120853","DOIUrl":null,"url":null,"abstract":"Background. Cholecalciferol is used in a minority of patients due to fear of prolonged hypercalcemia and renal toxicity","PeriodicalId":305591,"journal":{"name":"Family Medicine & Primary Care Review","volume":"59 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of relative frequency of treatment response and complications incidence in two therapeutic groups of patients with hypoparathyroidism treated with 1,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol referred to clinics of Ahwaz educational hospitals in the years 2010–2020\",\"authors\":\"S. Ghaderian, A. Sadrian, H. Rashidi, A. Sedaghat\",\"doi\":\"10.5114/fmpcr.2022.120853\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background. Cholecalciferol is used in a minority of patients due to fear of prolonged hypercalcemia and renal toxicity\",\"PeriodicalId\":305591,\"journal\":{\"name\":\"Family Medicine & Primary Care Review\",\"volume\":\"59 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Family Medicine & Primary Care Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/fmpcr.2022.120853\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Family Medicine & Primary Care Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/fmpcr.2022.120853","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Comparison of relative frequency of treatment response and complications incidence in two therapeutic groups of patients with hypoparathyroidism treated with 1,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol referred to clinics of Ahwaz educational hospitals in the years 2010–2020
Background. Cholecalciferol is used in a minority of patients due to fear of prolonged hypercalcemia and renal toxicity
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
